Pfizer Research Grant: Clinical Application Of ATM-AVI In Patients With CRE Infections

Pfizer Research Grant: Clinical Application Of ATM-AVI In Patients With CRE Infections

Due Date: 10/15/2025

Competitive research grant to evaluate the clinical effectiveness of ATM-AVI (aztreonam–avibactam) in patients with carbapenem-resistant Enterobacterales (CRE), including MBL-producing CRE, across hospitals in mainland China and Hong Kong.

Eligibility Criteria:

  • Principal Investigator and institution must be based in mainland China or Hong Kong.

  • Only organizations are eligible to receive funding (not individuals or independent practice groups).

  • PI must hold an MD, PhD, or equivalent medical/clinical research degree and be employed or contracted by the applying institution.

  • Institutions must be able to receive award funding directly from Pfizer Investment Co., Ltd. or Pfizer Corporation Hong Kong Limited.

Funding Details:

  • Up to USD 35,000 per project.

  • Total available budget: USD 413,000.

  • Project duration: 12 to 36 months.

Deadline:

  • Application Due: October 15, 2025 (23:59 EST).

  • Award Notification: January 15, 2026.

  • Project Start: May 16, 2026 – End: May 15, 2029.

Where To Go For Further Information: